
TransCode Therapeutics Implements 1-for-28 Reverse Stock Split to Maintain Nasdaq Compliance
TransCode Therapeutics will execute a reverse stock split to increase its per-share price and meet Nasdaq listing requirements, reducing outstanding shares from 23.3 million to approximately 833,620.
Read full story




















